Targeted Cancer Therapy: Initial High Concentration May Slow Down Selection for Resistance

“Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance.”

Listen to an audio version of this press release

BUFFALO, NY- August 6, 2024 – On July 28, 2024, Mikhail V. Blagosklonny M.D., Ph.D., from Roswell Park Comprehensive Cancer Center published a new editorial in Volume 16, Issue 14 of Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science), entitled, “Targeted cancer therapy: the initial high concentration may slow down the selection for resistance.”

“Unfortunately, any targeted therapy is, always, started with low levels of the drug in the organism, selecting for drug resistance. One should propose that initial drug levels must be maximized, and durations may be minimized, ideally, as portions of preemptive combination of targeted drugs.”

Read the full paper: DOI: https://doi.org/10.18632/aging.206046

Corresponding Author: Mikhail V. Blagosklonny - Blagosklonny@oncotarget.com, Blagosklonny@rapalogs.com

Keywords: aging, lung cancer, resistance, brain metastases, METex14, capmatinib, rapamycin

Click here to sign up for free Altmetric alerts about this article.